Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...

Equities research analysts at Leede Financial boosted their FY2025 earnings per share (EPS) estimates for shares of ...

Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh ...

RBC Capital lowered the firm’s price target on Oncolytics (ONCY) to C$5 from C$6 and keeps an Outperform rating on the shares.Optimize Your ...

Maxim lowered the firm’s price target on Oncolytics (ONCY) to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model ...

Oncolytics Biotech (ONCY) has disclosed a new risk, in the Corporate Activity and Growth category. Oncolytics Biotech faces significant business ...